Join this FREE, 75-minute online webinar to gain access to insights and learn about groundbreaking treatments to chronic mental health conditions.
An interesting question is how psychedelics differ from conventional antidepressants that also work on the serotonin system. A trial has just completed at Imperial College comparing a 6-week SSRI escitalopram treatment versus two psilocybin therapy sessions for treatment of depression. Robin Carhart-Harris (UK) will report on the results of this exciting trial during this webinar and answer questions.
WEBINAR SESSION
Date: Wednesday 24 March 2021
Time: 7:55pm for 8:00pm start – 9:15pm (incl Q&A) (AEDT)
The presentation WILL BEGIN AT 8:00pm.
Location: Online. A link will be emailed to you with the viewing details once you have registered.
Following the presentation there will be a Q & A panel with Dr Robin Carhart-Harris and Tania de Jong AM. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
Support these events:
Whilst our webinars are free of charge, we strongly encourage you to make a donation and support our important mission of making these therapies available through our medical system. This can be done at the time of reserving your ticket. Please share these events with your networks.
More about medicinal psychedelic treatments:
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
The Presenters
Prof Robin Carhart-Harris (USA)
BSc, Ph.D
Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, he has run and overseen brain imaging studies involving LSD, psilocybin, MDMA and DMT, plus a clinical trial of psilocybin for treatment-resistant depression, and a current study comparing psilocybin with escitalopram for major depressive disorder. In 2019, he set-up the Centre for Psychedelic Research at Imperial and he also an honorary position with the University of Oxford. Two of his most influential works include the ‘Entropic Brain Hypothesis’ and ‘REBUS and the anarchic brain’.